Kohlberg Kravis Roberts & Co. L.P. Impel Pharmaceuticals Inc Transaction History

Kohlberg Kravis Roberts & Co. L.P.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2021 Nov 15, 2021	BUY	$8.38 - $26.13 $2.79 Million - $8.71 Million	333,332 Added 8.77%	4,135,971 $50.4 Million
Q2 2021 Aug 16, 2021	BUY	$7.33 - $15.2 $27.9 Million - $57.8 Million	3,802,639 New	3,802,639 $33.7 Million

14.4K

Ticker IMPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,738,800
Market Cap $475K
Description
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The c...

Get notified when there are updates to the investment portfolio of Kohlberg Kravis Roberts & Co. L.P., based on Form 13F filings with the SEC.

Stay updated on Kohlberg Kravis Roberts & Co. L.P. with notifications on news.